Nutrition, while essential for our daily health, remains largely mysterious. We understand the benefits of plant-based foods but often don’t know the underlying reasons. Similarly, the role of our gut microbiome—the community of bacteria aiding in the digestion of these foods—has largely been unexplored. A new study published in Cell offers insights into how we might harness these intestinal microbes to break down plant compounds called phenolic glycosides, which could unlock new methods for managing inflammation and infections.
The Mystery of Plant Compounds and Their Impact on Health
Plants produce a variety of compounds for purposes such as attracting pollinators, deterring herbivores, and protecting against bacteria. One of the most intriguing categories of these compounds is phenolic glycosides. These molecules pair a sugar molecule with small bioactive molecules, which are believed to have health benefits for humans. The question researchers sought to answer: How do these compounds behave when ingested, and how can they affect human health?
Seth Rakoff-Nahoum, MD, PhD, from Boston Children’s Hospital, specializing in Infectious Diseases and Gastroenterology, led the study to uncover how these plant compounds interact with our gut microbiota. The team focused on how intestinal microbes use specialized enzymes to metabolize phenolic glycosides, breaking down sugar molecules for their own benefit while liberating smaller molecules with potential health benefits.
The Role of Intestinal Microbes in Regulating Health
The research team concentrated on Bacteroides, a prominent group of bacteria in the human gut microbiome, to understand their role in processing these plant compounds. By feeding a variety of phenolic glycosides to 52 strains of Bacteroides and Parabacteroides, they mapped which bacteria could metabolize these compounds effectively and identified the enzymes involved.
The findings were significant. The study revealed that some of these small molecules could regulate intestinal inflammation and bolster resistance against intestinal pathogens. Rakoff-Nahoum believes these insights could lead to new approaches for treating inflammatory bowel disease (IBD) and Clostridioides difficile (C. diff) infections—conditions that pose significant health risks.
Targeting Inflammation and C. Diff Infections
To delve deeper into how intestinal bacteria interact with these compounds, the researchers conducted experiments using mouse models of IBD and C. difficile infections. Their results showed that certain small molecules released by Bacteroides enzymes could selectively inhibit C. difficile colonization in the intestines.
Among the compounds studied, resveratrol—a molecule found in grapes and red wine—was particularly promising. When released from its parent compound, polydatin, resveratrol acted as an antibiotic and successfully inhibited C. difficile in mice.
Another compound, salicin, found in willow bark and known for its conversion to salicylic acid (the active ingredient in aspirin), displayed beneficial effects in the intestine. When metabolized by Bacteroides, salicin was transformed into saligenin, a molecule that regulates intestinal homeostasis and balances the immune response. The study showed that strains of Bacteroides capable of producing the necessary enzyme were able to protect against colitis, whereas those lacking the enzyme did not. Saligenin itself was found to be protective as well.
A New Path to Treatment
Rakoff-Nahoum emphasized the potential of these discoveries to shape future therapeutic approaches. He envisions treatments that could combine plant-derived phenolic glycosides with the bacterial enzymes responsible for their breakdown, or potentially even with the bacteria themselves. The research team has applied for patents related to the use of these compounds in treating IBD and C. difficile infections.
Scott Snapper, MD, PhD, Chief of the Division of Gastroenterology, Hepatology, and Nutrition at Boston Children’s, believes this research has significant therapeutic potential. “In my mind, this paper opens up a field and has the potential to have major therapeutic ramifications,” he said.
As researchers continue to explore the relationship between gut microbiota and plant-based compounds, these findings offer a promising glimpse into how our intestinal bacteria could one day be harnessed to combat inflammation and infections, unlocking new treatments and enhancing the health benefits of our diets.
You Might Be Interested In:
-
Study Links High Sodium Intake to Increased Risk of General and Abdominal Obesity
-
Study Shows Artificial Intelligence Can Improve Intravenous Nutrition for Premature Babies
-
Time-Restricted Eating Combined with Exercise May Boost Fat Loss
